Phenylbutazone pharmacokinetics and bioavailability in the Dromedary camel (camelus dromedarius)

A. Kadir, B. H. Ali, G. A L Hadrami, A. K. Bashir, M. F. Landoni, P. Lees

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Phenylbutazone was administered intravenously and intramuscularly at a dosage rate of 4.4 mg/kg to a group of 6 female camels in a two-period crossover study. After intravenous (i.v.) administration, disposition was characterised by a two-compartment open model, with a low volume of distribution (0.174 l.kg-1), and distribution and elimination half-lives of 0.43 and 12.51 h, respectively. After intramuscular (i.m.) dosing absorption was relatively rapid with absorption half-time and time of maximal concentration values of 1.14 and 3.95 h, respectively. Plateau concentrations of phenylbutazone in plasma were obtained between 2 and 12 h and mean bioavailability was 97%, although this was subject to wide inter-animal differences. Plasma concentrations of the phenylbutazone metabolite, oxyphenbutazone, were low after iv dosing and generally undetectable after im administration, indicating that it is unlikely to contribute significantly to the pharmacological effects produced by phenylbutazone administration. An indication was obtained that phenylbutazone inhibited the ex vivo synthesis of serum thromboxane B2 (TxB2) for 24 h after i.v. dosing, but this finding requires confirmation.

Original languageEnglish
Pages (from-to)54-60
Number of pages7
JournalJournal of Veterinary Pharmacology and Therapeutics
Volume20
Issue number1
Publication statusPublished - 1997

Fingerprint

phenylbutazone
Phenylbutazone
Camelus
Camelus dromedarius
Biological Availability
pharmacokinetics
bioavailability
Pharmacokinetics
Oxyphenbutazone
Thromboxane B2
thromboxanes
camels
intravenous injection
Intravenous Administration
Cross-Over Studies
half life
plateaus
Pharmacology
metabolites
synthesis

ASJC Scopus subject areas

  • Pharmacology
  • veterinary(all)

Cite this

Phenylbutazone pharmacokinetics and bioavailability in the Dromedary camel (camelus dromedarius). / Kadir, A.; Ali, B. H.; Hadrami, G. A L; Bashir, A. K.; Landoni, M. F.; Lees, P.

In: Journal of Veterinary Pharmacology and Therapeutics, Vol. 20, No. 1, 1997, p. 54-60.

Research output: Contribution to journalArticle

Kadir, A. ; Ali, B. H. ; Hadrami, G. A L ; Bashir, A. K. ; Landoni, M. F. ; Lees, P. / Phenylbutazone pharmacokinetics and bioavailability in the Dromedary camel (camelus dromedarius). In: Journal of Veterinary Pharmacology and Therapeutics. 1997 ; Vol. 20, No. 1. pp. 54-60.
@article{893196e11265423ea451483b1144ac13,
title = "Phenylbutazone pharmacokinetics and bioavailability in the Dromedary camel (camelus dromedarius)",
abstract = "Phenylbutazone was administered intravenously and intramuscularly at a dosage rate of 4.4 mg/kg to a group of 6 female camels in a two-period crossover study. After intravenous (i.v.) administration, disposition was characterised by a two-compartment open model, with a low volume of distribution (0.174 l.kg-1), and distribution and elimination half-lives of 0.43 and 12.51 h, respectively. After intramuscular (i.m.) dosing absorption was relatively rapid with absorption half-time and time of maximal concentration values of 1.14 and 3.95 h, respectively. Plateau concentrations of phenylbutazone in plasma were obtained between 2 and 12 h and mean bioavailability was 97{\%}, although this was subject to wide inter-animal differences. Plasma concentrations of the phenylbutazone metabolite, oxyphenbutazone, were low after iv dosing and generally undetectable after im administration, indicating that it is unlikely to contribute significantly to the pharmacological effects produced by phenylbutazone administration. An indication was obtained that phenylbutazone inhibited the ex vivo synthesis of serum thromboxane B2 (TxB2) for 24 h after i.v. dosing, but this finding requires confirmation.",
author = "A. Kadir and Ali, {B. H.} and Hadrami, {G. A L} and Bashir, {A. K.} and Landoni, {M. F.} and P. Lees",
year = "1997",
language = "English",
volume = "20",
pages = "54--60",
journal = "Journal of Veterinary Pharmacology and Therapeutics",
issn = "0140-7783",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Phenylbutazone pharmacokinetics and bioavailability in the Dromedary camel (camelus dromedarius)

AU - Kadir, A.

AU - Ali, B. H.

AU - Hadrami, G. A L

AU - Bashir, A. K.

AU - Landoni, M. F.

AU - Lees, P.

PY - 1997

Y1 - 1997

N2 - Phenylbutazone was administered intravenously and intramuscularly at a dosage rate of 4.4 mg/kg to a group of 6 female camels in a two-period crossover study. After intravenous (i.v.) administration, disposition was characterised by a two-compartment open model, with a low volume of distribution (0.174 l.kg-1), and distribution and elimination half-lives of 0.43 and 12.51 h, respectively. After intramuscular (i.m.) dosing absorption was relatively rapid with absorption half-time and time of maximal concentration values of 1.14 and 3.95 h, respectively. Plateau concentrations of phenylbutazone in plasma were obtained between 2 and 12 h and mean bioavailability was 97%, although this was subject to wide inter-animal differences. Plasma concentrations of the phenylbutazone metabolite, oxyphenbutazone, were low after iv dosing and generally undetectable after im administration, indicating that it is unlikely to contribute significantly to the pharmacological effects produced by phenylbutazone administration. An indication was obtained that phenylbutazone inhibited the ex vivo synthesis of serum thromboxane B2 (TxB2) for 24 h after i.v. dosing, but this finding requires confirmation.

AB - Phenylbutazone was administered intravenously and intramuscularly at a dosage rate of 4.4 mg/kg to a group of 6 female camels in a two-period crossover study. After intravenous (i.v.) administration, disposition was characterised by a two-compartment open model, with a low volume of distribution (0.174 l.kg-1), and distribution and elimination half-lives of 0.43 and 12.51 h, respectively. After intramuscular (i.m.) dosing absorption was relatively rapid with absorption half-time and time of maximal concentration values of 1.14 and 3.95 h, respectively. Plateau concentrations of phenylbutazone in plasma were obtained between 2 and 12 h and mean bioavailability was 97%, although this was subject to wide inter-animal differences. Plasma concentrations of the phenylbutazone metabolite, oxyphenbutazone, were low after iv dosing and generally undetectable after im administration, indicating that it is unlikely to contribute significantly to the pharmacological effects produced by phenylbutazone administration. An indication was obtained that phenylbutazone inhibited the ex vivo synthesis of serum thromboxane B2 (TxB2) for 24 h after i.v. dosing, but this finding requires confirmation.

UR - http://www.scopus.com/inward/record.url?scp=0031044829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031044829&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 54

EP - 60

JO - Journal of Veterinary Pharmacology and Therapeutics

JF - Journal of Veterinary Pharmacology and Therapeutics

SN - 0140-7783

IS - 1

ER -